top of page

Ding Ding

Past #1 Institutional Investor Healthcare Analyst; Founder, Augere Group

Ding Ding, Ph.D. is the Founder and Chairwoman of Augere Group, which provides corporate finance advisory to the healthcare industries.

Ding Ding, Ph.D was the CFO of Shouti, a highly innovative clinical stage biotech company using advanced computational and structure-based technology to develop world-class small molecule medicines to replace biologics and peptide drugs. Dr. Ding had 20 years of healthcare investment banking and equity research experience in New York, Hong Kong and China with leading global banks. Prior to joining Shouti, Dr. Ding was the head of APAC Healthcare Investment Banking and Capital Markets at Credit Suisse, and head of China healthcare investment banking at Barclays and Nomura respectively. Prior to her banking career, Dr. Ding spent 9 years as an equity research analyst, covering US large cap pharma at Lehman Brothers in the #1 Institutional Investor ranked research team, and as the head of China healthcare equity research at UBS.

Dr. Ding received her Ph.D. in pharmacology/neuroscience from State University of New York, Downstate Medical Center, her MBA in finance from the Wharton School, University of Pennsylvania, and BS in electrical engineering from Huazhong University of Science and Technology in China.

Dr. Ding and her team advised some of the most important landmark IPOs, private capital raise and M&A transactions across all healthcare subsectors over the past decade, including:

- 4 out of the 5 largest life science IPOs out of Asia: Beigene ($903m Hong Kong IPO), Zai Lab ($750m Hong Kong IPO), Junshi ($453m Hong Kong IPO), Everest ($451m Hong Kong IPO)

- Carsgen: Largest pre-IPO financing in the CART space: ($186m pre IPO round)

- Tigermed: Largest IPO in the CRO sector in Asia: ($1.59bn Hong Kong IPO)

- Genetron:Largest ever cancer genomic IPO on Nasdaq:($256m Nasdaq IPO)

- Venus Medtech:1st chapter 18A medtech IPO: ($381m Hong Kong IPO)

- Two largest private capital raise for Healthcare companies out of Asia: $600m crossover financing for Ruipeng, and $500m F round financing for WeDoctor

- Two largest healthcare follow-on offerings out of Asia: Beigene ($2.1bn), AliHealth ($1.3bn)

- Largest healthcare SPAC/de SPAC out of Asia: New Frontier’s acquisition of Chindex ($1.4bn)

- Largest outbound Healthcare M&A for a Chinese buyer: Luye’s acquisition of Healthe (Australia) for A$938m

- 2nd largest inbound M&A into China in medtech sector: Stryker's acquisition of Trauson for $764m

Ding Ding
bottom of page